Year: 2017
Type: article
Abstract: Subtype N CR PR ORR DLBCL 6 0 1 17% MCL 4 1 3 100% 53% of evaluable CLL pts had high-risk cytogenetics and 4/6 DLBCL pts were non-GCB.One CLL pt (17p/11q del) ref to PI3Kδ and ibrutinib achieved a CR.Med time on study is 10 mos (range 1 -27 mos).Med DOR not reached (range 3 -24 mos).Conclusions: This is the first known triplet combination of an anti-CD20 mAb + PI3Kδ + BTK inhibitor.The combination of UTX, TGR-1202, and ibrutinib has been well tolerated with activity observed across heavily pre-treated and high-risk B-cell malignancies.Expansion cohorts at the highest dose (800 mg TGR-1202 + full dose ibrutinib) are underway.Future trials for the triplet are warranted.
Source: Hematological Oncology
DOI: 10.1002/hon.2437_103
Institutions: Hospices Civils de Lyon, Mayo Clinic, Hospital Clínic de Barcelona, Consorci Institut D'Investigacions Biomediques August Pi I Sunyer, Universitat de Barcelona, Université Paris Sciences et Lettres, Institut Curie, Aix-Marseille Université, Institut Paoli-Calmettes, Inserm, Centre Hospitalier Universitaire de Rennes, Université Rennes 1, Centre Léon Bérard, Assistance Publique – Hôpitaux de Paris, University of Iowa, Centre Hospitalier Régional et Universitaire de Nancy, Laboratoire d'hématologie, Centre Henri Becquerel, Ghent University Hospital, Hôpital Lyon Sud
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W2622815487